ANALIZE MEDICALE DE LABORATOR
            Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
            Selectati o categorie din lista de mai jos:
            
         
     
    
    
    
        Solutie antistress!
 Construieste poduri :)
        
        
        Prinde pisica neagra :)
        
     
 
Many Heart Attack Patients Don't Get Best Emergency Treatment
Far more of today's 
heart attack patients receive emergency angioplasty treatment or 
clot-busting drugs to re-open their clogged heart arteries than even a 
decade ago, a new study finds.
 
    
But 10 percent of patients who could benefit from this urgent treatment  
-- which is known to save lives and prevent lasting damage to the heart 
muscle -- don't get it at all, the study shows.
 
    
And the chance of missing out on lifesaving emergency treatment was 
highest among those patients whose heart attack symptoms don't include  
typical symptoms like chest pain, those who didn't reach the hospital until 
six or more hours after the start of their attack, women, people over age 
75, and non-white people.
 
    
The study, published in the American Journal of Medicine by a team led  
by cardiologists from the University of Michigan Cardiovascular Center and 
the Yale University School of Medicine, is based on data from 238,291 
patients who had had a type of heart attack for which this therapy is 
appropriate between 1994 and 2003.
 
    
It's the most current and comprehensive look at the use of emergency 
"reperfusion" -- a term that describes treatments that can break up blood 
clots and other blockages in the tiny blood vessels of the heart and 
restore blood flow to the heart muscle.
 
    
In the ten-year study period, the percentage of patients who could have 
received emergency reperfusion but didn't declined from more than 20 
percent to 10 percent - a notable achievement that the authors attribute to 
the increasing evidence of the benefit of emergency angioplasty, and the 
rise in the availability of the treatment at American hospitals and 
concerted national efforts to improve care.
 
    
The database used for the study, called the National Registry of 
Myocardial Infarction, includes detailed information about each patient's 
condition that can be used to determine if they would meet the criteria to 
receive emergency angioplasty or treatment with fibrinolytic (clot-busting)  
medications.
 
    
But it's those details that reveal the troubling gap between the number 
of patients who could have received the treatments, and those who actually 
did.
 
    
"We may never be able to get to 100 percent, but 10 percent of eligible   
patients going untreated is still too many," says first author Brahmajee 
Nallamothu, M.D., MPH, assistant professor of cardiovascular medicine at 
the U-M Medical School. "We hope our study highlights the opportunities to 
improve care and particularly some of the "at-risk" subgroups still less 
likely to receive reperfusion therapy despite eligibility, so that we can 
focus our clinical efforts on them."
 
    
Adds senior author Harlan Krumholz, M.D., S.M., "This study has good  
and bad news. We have definitely made progress in treating appropriate 
patients, but our findings indicate that we need to improve further to be 
sure that no patient who could benefit from this treatment is missed." 
Krumholz is the Harold H. Hines, Jr. Professor of Medicine in the Section 
of Cardiovascular Medicine and director of the Yale-New Haven Hospital 
Center for Outcomes Research and Evaluation.
 
    
The study was funded by the National Heart, Lung and Blood Institute of 
the National Institutes of Health. Genentech, Inc. provided the researchers  
access to the registry, which it sponsors.
 
    
To track the changes in acute (emergency) reperfusion therapy over 
time, the researchers divided the study data into three time periods: June 
1994 through May 1997, June 1997 through May 2000, and June 2000 through   
May 2003.
 
    
The rise in emergency angioplasty was fastest from the first time 
period to the second; the rate of increase leveled off from the second time  
period to the third. Correspondingly, the number of patients receiving 
medication-based reperfusion dropped over the study period. 
 
    
This is an appropriate shift, says Nallamothu: shifting patients from 
clot-busting medications to emergency angioplasty may save 12 to 20 lives  
for every 1,000 heart attack patients treated, if the angioplasty is 
performed in a timely manner.
 
    
The study involved patients who had a particular type of heart attack, 
called STEMI, for ST-elevated myocardial infarction. Emergency angioplasty 
is considered the best immediate treatment for STEMI. However, the study 
did not look specifically at the time that elapsed from the moment the 
STEMI patient arrived at the hospital to the time when the reperfusion 
treatment began. This is often called "door to balloon time" because of the 
use of tiny artery- opening balloons in the angioplasty procedure.
 
    
Hospitals around the nation, including U-M and Yale, are taking part in 
a national campaign to reduce this time interval for patients who receive 
emergency angioplasty, and studies have shown that patients who are treated   
within an hour or two of arrival at the hospital do better in the long term 
than those who wait longer for angioplasty.
 
    
But the fact that 10 percent of possible emergency angioplasty 
candidates still aren't even getting the procedure at all is a significant  
issue of its own, the authors say. Increasing its use in these patients 
could save up to an additional 30 lives for every 1,000 heart attack 
patients treated when performed in a timely manner.
 
    
In fact, the authors state that hospitals should be judged in part by 
their ability to deliver acute reperfusion to as many candidate patients as 
possible. "Our findings support the incorporation of a measure of 
reperfusion use into national quality improvement efforts," they write. An 
American College of Cardiology/American Heart Association task force has 
endorsed this same idea.
 
    
In the meantime, the study results again point to the importance of 
rapid response to heart-attack symptoms by individuals and their loved ones  
-- and the need to recognize that chest pain may not occur in everyone who 
has a heart attack.
 
    
In the study, patients who came to the hospital with no chest pain but 
with other symptoms of heart attack were less than one-third as likely as 
those with chest pain to get emergency reperfusion treatment. Patients who  
waited six or more hours before they reached the hospital were 40 percent 
less likely to get emergency reperfusion.
 
University of Michigan Health System
http://www.med.umich.edu
		
Mulþi pacienþi atac de cord nu obþine cel mai bun tratament de urgenþã - Many Heart Attack Patients Don't Get Best Emergency Treatment - articole medicale engleza - startsanatate